Profile data is unavailable for this security.
About the company
Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.
- Revenue in AUD (TTM)687.57k
- Net income in AUD-8.24m
- Incorporated1986
- Employees3.00
- LocationPrescient Therapeutics LtdL 4 100 Albert RdSOUTH MELBOURNE 3205AustraliaAUS
- Phone+61 39692-7222
- Fax+61 39077-9233
- Websitehttps://ptxtherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotron Ltd | 1.65m | -3.44m | 18.95m | 4.00 | -- | -- | -- | 11.52 | -0.0038 | -0.0038 | 0.0018 | -0.0003 | 0.7108 | -- | -- | -- | -148.49 | -77.12 | -234.15 | -92.61 | -120.34 | -127.14 | -208.89 | -238.85 | -- | -- | -- | -- | 14.94 | 8.93 | 1.61 | -- | -- | -- |
| Invion Ltd | 3.74m | -5.63m | 20.30m | 8.00 | -- | 1.37 | -- | 5.42 | -0.0009 | -0.0009 | 0.0006 | 0.0022 | 0.217 | -- | 2.65 | -- | -32.63 | -19.46 | -34.28 | -20.50 | -- | -- | -150.33 | -70.20 | -- | -- | 0.00 | -- | -9.54 | -0.7235 | -248.51 | -- | 171.96 | -- |
| Tryptamine Therapeutics Ltd | 1.21m | -4.32m | 21.78m | -- | -- | 3.24 | -- | 18.04 | -0.0162 | -0.0162 | 0.0039 | 0.0062 | 0.2368 | -- | -- | -- | -84.69 | -- | -120.26 | -- | -- | -- | -357.70 | -- | -- | -21.62 | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| LBT Innovations Limited | 1.31m | -3.74m | 23.13m | 17.00 | -- | 13.20 | -- | 17.66 | -0.0032 | -0.0032 | 0.001 | 0.0011 | 0.1712 | 0.0959 | 2.52 | -- | -48.89 | -34.86 | -78.03 | -38.53 | 88.63 | -- | -285.50 | -513.87 | 2.56 | -12.08 | 0.5686 | -- | -39.04 | -14.71 | 83.40 | -- | -69.50 | -- |
| Bioxyne Ltd | 9.33m | -12.80m | 26.61m | 16.00 | -- | 7.38 | -- | 2.85 | -0.007 | -0.007 | 0.0064 | 0.0018 | 0.7646 | 3.78 | 10.33 | -- | -106.39 | -56.02 | -134.91 | -72.46 | 36.44 | 40.00 | -139.14 | -85.52 | 1.18 | -40.41 | 0.0526 | -- | 80.70 | 34.32 | -559.75 | -- | 50.56 | -- |
| Amplia Therapeutics Ltd | 4.44m | -4.50m | 27.21m | 1.00 | -- | 1.73 | -- | 6.13 | -0.0226 | -0.0226 | 0.0222 | 0.0572 | 0.2647 | -- | 2.05 | -- | -26.86 | -25.13 | -32.90 | -27.42 | -- | -- | -101.48 | -206.74 | -- | -- | 0.122 | -- | 286.42 | 144.81 | 27.86 | -- | -6.91 | -- |
| Tissue Repair Ltd | 548.09k | -4.14m | 29.02m | -- | -- | 1.61 | -- | 52.95 | -0.0684 | -0.0684 | 0.0091 | 0.2983 | 0.0262 | 0.00 | 1.22 | -- | -19.81 | -24.20 | -20.72 | -25.29 | 100.00 | -- | -755.00 | -10,570.14 | 14.34 | -- | 0.00 | -- | 4,842.86 | -- | 0.8698 | -- | -- | -- |
| Noxopharm Ltd | 2.41m | -3.58m | 29.22m | 1.00k | -- | 5.32 | -- | 12.14 | -0.0086 | -0.0086 | 0.0082 | 0.0188 | 0.2847 | -- | 2.00 | -- | -42.31 | -43.24 | -48.67 | -52.58 | -- | -- | -148.64 | -170.07 | -- | -- | -- | -- | -60.33 | -9.37 | 76.24 | -- | -- | -- |
| Prescient Therapeutics Ltd | 687.57k | -8.24m | 32.21m | 3.00 | -- | 1.78 | -- | 46.85 | -0.0102 | -0.0102 | 0.0009 | 0.0224 | 0.0284 | -- | 3.31 | -- | -33.97 | -28.85 | -37.31 | -30.66 | -- | -- | -1,198.14 | -2,096.39 | -- | -288.97 | 0.018 | -- | 49.77 | 56.99 | -17.61 | -- | -- | -- |
| Cynata Therapeutics Ltd | 417.71k | -9.74m | 34.33m | 0.00 | -- | 4.73 | -- | 82.18 | -0.0543 | -0.0543 | 0.0023 | 0.0402 | 0.0305 | -- | 1.85 | -- | -71.18 | -39.49 | -81.37 | -42.96 | -- | -- | -2,332.89 | -515.32 | -- | -- | 0.00 | -- | 18.38 | 16.51 | 31.75 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| DFA Australia Ltd.as of 31 May 2023 | 57.23k | 0.01% |
| Dimensional Fund Advisors LPas of 30 Apr 2024 | 0.00 | 0.00% |
